Assessing the Effect of Treatment Duration on the Association between Anti-Diabetic Medication and Cancer Risk by But, Anna et al.
RESEARCH ARTICLE
Assessing the Effect of Treatment
Duration on the Association between Anti-
Diabetic Medication and Cancer Risk
Anna But1*., Haining Wang2., Satu Ma¨nnisto¨3, Eero Pukkala4, Jari Haukka1
1. Hjelt Institute, University of Helsinki, Helsinki, Finland, 2. Department of Endocrinology and Metabolism,
Peking University Third Hospital, Beijing, China, 3. Department of Chronic Disease Prevention, National
Institute for Health and Welfare, Helsinki, Finland, 4. Finnish Cancer Registry, Helsinki, Finland
*anna.but@helsinki.fi
. These authors contributed equally to this work.
Abstract
Most studies that have evaluated the association between anti-diabetic medication
and cancer risk have suffered from methodological drawbacks. To avoid time-
related biases, we evaluated the effect of treatment duration on the cancer risk
among naive users of anti-diabetic medication as compared to non-users. In
addition, we addressed the influence of common risk factors such as smoking and
BMI. The study population comprised 23,394 participants of FINRISK surveys. Data
on cancer and anti-diabetic medication were linked with the study cohorts. We
applied Lexis tabulation to the data and analyzed split records by using Poisson
regression. Changes in cancer incidence in relation to treatment duration were
examined by modeling the rate ratio (RR). After a median follow-up of 9 years, 53
cancer cases among users of anti-diabetic medication and 1,028 among non-users
were diagnosed. No significant difference in cancer risk between users and non-
users was observed after adjustment. The RR for all medication regardless of its
duration was 1.01 [95% CI 0.75–1.33], and 1.37 [0.94–1.94] for period of 1–4 years.
The results were similar for metformin, sulfonylurea, and insulin. This study
demonstrates that evaluation of the variation in cancer risk in relation to treatment
duration is of particular importance for enhancing the accuracy of conclusions on
the link between exposure to anti-diabetic medication and cancer risk.
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Introduction
Numerous epidemiological studies have demonstrated an association between
diabetes and cancer risk, although the findings have not been entirely consistent
[1,2]. The underlying mechanisms are still unclear, but it is suggested that risk
factors common to both disorders may explain this association to some degree.
On the other hand, a causal effect of elevated glucose levels resulting from an
absolute or relative deficiency of insulin as well as an effect of anti-diabetic
medication (ADM) might be responsible for the potential biological link between
the two diseases. It is also possible that the association between diabetes and
cancer risk is affected by a combination of these factors [3].
Although there is extensive evidence for the association between ADM and
cancer risk, the interpretation of results is not straightforward due to the variety of
approaches to the study design and analysis used, heterogeneity of comparator
populations, inadequate control for confounding, and time-related biases
potentially involved [4–6]. The complexity of both diabetes and cancer along with
the wide range of treatment options in diabetes and methodological problems
have created a demanding challenge for research into the link between ADM and
cancer risk. Recently, the key role of evaluation of the dosage and/or duration
effect in capturing the true association between ADM and cancer risk has been
emphasized [7–9].
In this study on FINRISK cohorts, we aimed to examine the relationship
between cancer risk and ADM. In particular, our aim was to analyze the variation
in cancer risk as a function of the duration of ADM and to explore the role of the
common risk factors in the association of interest.
Materials and Methods
Study population
The study population comprised three samples from independent cross-sectional
population surveys, known as the National FINRISK Study, conducted in 1997,
2002, and 2007. The main aim of the FINRISK surveys, carried out at five-year
intervals since 1972, has been to assess the levels of coronary risk factors in the
population of Finland [10]. For each survey, a sample was randomly drawn from
the Finnish Population Information System, stratified by sex, 10-year age groups,
and geographical areas according to the standardized international protocols [11].
The study was conducted according to the guidelines laid down in the Declaration
of Helsinki, and the study protocol was approved by the Ethics Committee of
Helsinki and Uusimaa Hospital. All study participants signed the informed
consent form. The survey included a self-administered questionnaire, which was
sent by mail to all selected subjects together with an invitation to a health
examination. The questionnaire was completed in advance at home and was
reviewed during the health examination when measurements were carried out.
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The surveys were conducted in the provinces of North Karelia and Kuopio in
eastern Finland, in southwestern Finland, in the province of Oulu and Lapland in
Northern Finland, and in the cities of Helsinki and Vantaa (the metropolitan
area). Approximately half of the total Finnish population of 5.5 million lives in the
sampled regions, which incorporate both urban and rural areas. In FINRISK
surveys, the participation rates have been relatively high despite the continuous
decline, showing a slight regional variation and being consistently lower for men
as compared to women, for which rates were 72–81% in 1997 and 69–73% in 2007
for the age group common for all surveys [10]. The surveys were carried out using
both a questionnaire and health examination in all regions except Lapland in
2007, where survey was limited to the questionnaire alone. There were also those
outside Lapland who participated by returning questionnaire only. In 2007, more
than 65% of women took part in the survey in its entirety. Only those FINRISK
participants who both returned the questionnaire and underwent the health
assessment were included in the study population, which comprised 24,812
individuals. In 2007, more than 65% of women took part in the survey in its
entirety.
In this study, we considered only the first primary cancer of any site except for
skin cancer other than melanoma, and regarded all cancers combined as the main
outcome of interest. In addition, two subgroups of cancer sites that are known to
be related to either tobacco smoking or obesity were formed based on
epidemiological evidence (Table S1) [12]. The follow-up time was defined for
each individual as the time from entering the FINRISK study in 1997, 2002, or
2007 until December 31, 2010, the diagnosis of any cancer, or the date of death,
whichever happened first. The date of entering FINRISK was determined
according to the date the individual visited the study site, which took place from
January to March of the survey year.
Potential confounding variables
Based on the questionnaire responses, the individuals were classified as never, ex-,
and current smokers and were divided into three groups according to their
alcohol consumption. The number of drinks consumed during the week
preceding examination was enquired and each drink was converted to 12 g of
pure alcohol. We distinguished those not using alcohol (never or no alcohol
exposure for the last 12 months), moderate users (,168 g or 14 portions per week
for men, ,84 g or 7 portions per week for women) and heavy users (§168 g/
week for men, §84 g/week for women). BMI was calculated as the weight in
kilograms divided by the square of the height in meters measured at baseline. BMI
was divided into four categories according to WHO recommendations [13].
Individuals with BMI less than 18.5 kg/m2 were categorized as underweight, 18.5–
24.9 kg/m2 as normal weight, 25–25.9 kg/m2 as overweight, and 30 kg/m2 or
more as obese. There were missing values for BMI, smoking, and alcohol
consumption. In order to analyze all available data on cancer and drug exposure,
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for each variable with missing values we assigned an additional category denoted
as ‘‘missing’’.
Register data
Incident cancers were identified by linkage with the Finnish Cancer Registry,
which has collected data on all incident cancer cases in Finland since 1953 [14].
Those with a history of cancer at baseline (N5870) were excluded from the study.
FINRISK data were also linked to the register of death records of Statistics Finland
(http://www.stat.fi). All individuals who had started anti-diabetic medication
(ADM) after entering FINRISK and before December 31, 2010, were identified
from the Prescription Register of the Finnish Social Insurance Institution [15].
This register contains information on all prescribed medicines that have been
purchased since 1995. Each prescription record includes a personal identity
number, the date of purchase, the ATC code of the medicine, the number of
packages purchased and the disease code assigned for reimbursement approval
[16]. Information on the size of the packages purchased was not available. We
excluded the prevalent users of ADM (N5548) by applying a half-year wash-out
period. The final sample comprised 23,394 individuals (11,184 men and 12,210
women).
Exposure
Although FINRISK data included information on the self-reported diagnosis of
diabetes, and prescription records incorporated a disease code used for
reimbursement approval, no specific information was available on either the type
of diabetes or the date of the physician’s diagnosis. It is most likely that the study
population treated with ADM consisted of both type 1 and type 2 diabetic
patients. As reliable separation of type 1 and 2 was not possible, all individuals
with ADM were simply considered as diabetic patients.
ADM aims at lowering blood glucose levels, and includes a variety of medicines
working in different ways. In this study, we considered the effect of well-
established medicines, which were classified into five treatment groups according
to their ATC codes: metformin, sulfonylurea (including glinides), insulin and its
analogues, thiazolidinedione (TZD), and others. Due to the small number of
users, TZD/other medicines were only analyzed as a part of the total exposure to
ADM. Oral anti-diabetic medication (OADM) was defined as anti-diabetic
medicines other than insulin and its analogues.
Individuals who started ADM during the study period were considered as naive
users. To avoid uncertainty in the sequence of ADM and cancer diagnoses, we
regarded the cancer cases diagnosed within one month after the initiation of
medication as being diagnosed in non-users. After first purchase, individuals were
regarded as users, regardless of nonpersistence with medication. For each
treatment group and ADM as a whole, a variable indicating the status of drug use
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(user, non-user) as well as a variable representing the time since initiation was
specified.
Statistical analyses
The data were processed using Lexis tabulation [17]. The individual follow-up
times were cut by the start of ADM and/or by the start of a particular treatment,
and split by the calendar time and time since initiation of ADM (3, 6, 12, 24, and
48 months) into intervals of short length (,0.7 years).
Based on tabulated data, a binary representation of exposure to ADM as a
whole with the categories ‘no ADM’ (reference) and ‘ADM’, and treatment-
specific representation with the categories ‘no ADM’ (reference), ‘other than
treatment of interest’, and ‘treatment of interest’ were constructed. In addition, we
defined an otherwise similar variable for each treatment but with the category
‘treatment of interest’ extended to three categories representing the duration of
treatment (#1, 1–4, .4 years).
For each potential risk factor, the cancer incidence rate ratio (RR) was assessed
by applying a univariate Poisson regression model. We used an offset term equal
to the natural logarithm of person-time to account for the differences in
population size between subgroups. In addition, the odds ratio (OR) was
evaluated using univariate logistic regression to quantify the contribution of the
same risk factors to the likelihood of initiating ADM.
Poisson regression was used to examine the ADM and its specific treatments.
RRs for users relative to non-users were calculated from the univariate models as
well as models adjusted for gender, current age, calendar time (defined as the
midpoint of each interval), BMI, and smoking. The effect of age was modeled by
using a restricted cubic (natural) spline with the knots at quartiles calculated for
cancer cases. For the calendar time, the use of a categorical variable with categories
defined according to quintiles was found to be more suitable. The significance of
each term added to the model was tested by performing an analysis of deviance
with the x2 test. Model selection was based on both the Akaike information
criterion and comparison between the models using the deviance test. The z-
values following a standard normal distribution were used to test against a two-
sided alternative hypothesis that the model coefficients were equal to zero. The p-
values corresponding to the z ratio were calculated and p,0.05 were considered
statistically significant.
Graphical output for the variation in RR according to treatment or diabetes
duration was provided by using restricted cubic splines. Knots for spline function
were defined using quartiles calculated for cancer cases. The first knot
corresponding to the start of metformin or sulfonylurea treatment was assigned to
zero to allow for allocation of the effect of other ADM already being used.
All statistical analyses were performed and graphs prepared using the package
Epi in R, which is free and open-source software [18].
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Results
After a median follow-up of 9 years, 1,028 cancer cases were diagnosed among
22,093 non-users and 53 among 1,301 individuals who started ADM during the
study period (Table 1). Metformin was the most commonly used medicine
(N51188), followed by sulfonylurea (N5365) and insulin (N5232). Cancers of
the prostate, breast, female genital organs, the colorectal tract and the lung
accounted for the majority of cases (Table S2). The crude incidence rate assessed
for all cancer sites was higher in users of ADM, being highest in insulin users.
Table 1. Baseline and exposure characteristics among non-users and those who started ADM during the study period, 1997–2010.
No ADM (N522,093) ADM (N51,301) Type of ADM
Metformin (N51,188) Sulfonylurea (N5365) Insulin (N5232)
Cancer cases, n 1,028 53 42 22 11
Median follow-up time (IQR) 8.8 (3.9–13.7) 8.9 (8.8–13.8) 8.9 (8.8–13.8) 13.6 (8.8–13.8) 13.3 (8.8–13.9)
Crude IR/1,000 PY (95% CI) 5.35 (5.02–5.69)* 9.93 (7.44–13.00) 9.27 (6.67–12.53) 10.27 (6.43–15.55) 12.46 (6.22–
22.30)
Age 48.0¡13.5* 61.0¡11.1 61.1¡10.9 62.0¡10.9 60.9¡12.4
Gender, male % 47.2%* 58.7% 57.8% 64.1% 68.3%
FINRISK year
1997 6928 (31.4%)* 633 (48.5%) 568 (47.7%) 240 (66.3%) 143 (61.6%)
2002 8256 (38.6%) 472 (36.2%) 436 (36.6%) 105 (29.0%) 75 (32.3%)
2007 6906 (31.3%) 199 (15.3%) 186 (15.6%) 17 (4.7%) 14 (6.0)
BMI (kg/m2)
,18.5 158 (0.7%)* / / / /
18.5–24.9 8026(36.4%)* 96(7.4%) 68 (5.7%) 28 (7.7%) 23 (9.9%)
25.0–29.9 7958 (36.0%) 458 (35.2%) 411 (34.5%) 135 (37.3%) 81 (34.9%)
.530 3429 (15.5%) 725 (55.8%) 696 (58.5%) 189 (52.2%) 121 (52.2%)
Missing 2522 (11.4%) 22 (1.7%) 15 (1.3%) 10 (2.8%) 7 (3.0%)
Smoking
Never 11525 (52.2%)* 594 (45.7%) 552 (46.4%) 157 (43.4%) 102 (44.0%)
Former 4861(22.0%) 346 (26.6%) 318 (26. 9%) 102 (28.2%) 60 (25.8%)
Current 5436 (24.6%) 323 (24.8%) 287 (24.1%) 91(25.1%) 62 (26.7%)
Missing 271 (1.2%) 38 (2.9%) 31 (2.6%) 12 (3.31%) 8 (3.5%)
Alcohol consumption
None 7820 (35.4%)* 525 (40.3%) 486 (40.9%) 159 (43.5%) 100 (43.1%)
Moderate 10375 (47.0%) 499 (38.4%) 455 38.3%) 131(34.3%) 81 (34.9%)
Heavy 3136 (14.2%) 198 (15.2%) 181 (15.2%) 42 (13.2%) 31 (13.4%)
Missing 762 (3.4%) 79 (6.1%) 66 (5.6%) 33 (9.0%) 20 (8.6%)
Median exposure duration (IQR) / 3.2 (1.6–6.1) 3.0 (1.5–5.6) 5.6 (2.9–8.5) 3.0 (1.2–5.7)
Combined therapy{ (%) / 531 (40.8%) 506 (42.6%) 320 (87.7%) 196 (84.5%)
{Combined therapy: treated with ADM of more than one type (insulin, metformin, sulfonylurea, TZD, others).
*Compared with those without ADM, P , 0.001.
Abbreviations: ADM, anti-diabetic medication; N, size of the population; n, number of incident cancer cases; IQR, inter-quartile range; IR, incidence rate; PY,
person-years; CI, confidence intervals.
doi:10.1371/journal.pone.0113162.t001
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Similar differences were seen for the cancer sites related to tobacco smoking, while
only two cancer cases of sites related to obesity were found among users of ADM
(Table S3). Users of ADM were older at baseline and comprised more men and
obese individuals (BMI§30). Among users, there were more former smokers and
fewer who had never smoked at baseline, and they more frequently reported not
drinking alcohol. The median exposure duration was around 3 years for ADM and
its treatment groups, except for sulfonylurea, for which it was almost 6 years.
More than 40% of the ADM users and most of the insulin and sulfonylurea users
had undergone combined therapy.
Aging, male gender, overweight, obesity, and smoking, both current and
past, were all associated with an increased risk of both cancer and the initiation
of ADM when their effect was modeled separately (Table S3). The risk of
cancer as well as initiating anti-diabetic treatment was found to be lower in
those with moderate use of alcohol when compared to non-drinkers, while no
significant difference in cancer risk was seen between non-drinkers and heavy
drinkers.
According to the Akaike information criterion and deviance test, the best fit
was provided by a Poisson regression model with adjustment for age, gender,
calendar time, BMI, and smoking, also including interactions between age and
sex, and age and BMI. RR calculated for all cancer sites regardless of ADM
duration was 1.86 [95% CI 1.39–2.42] in the unadjusted model (Table 2). After
adjustment for age, gender, and calendar time (Model I), and further
adjustment for BMI and smoking (Model II), no association was seen. The
results were similar for metformin, sulfonylurea, and insulin analyzed
separately. The crude RR of tobacco-related cancers was higher in users of
ADM when compared to non-users, but after adjustment no differences were
found (Table S4).
Duration analysis for any ADM yielded RRs ranging from 1.10 [95% CI 0.47–
2.12] for the first year to 2.44 [95% CI 1.67–3.43] during a period of 1–4 years,
and 1.58 [95% CI 0.91–2.54] for more than 4 years since the initiation, when no
adjustment was performed (Table 3). Although the RR of 1.47 [95% CI 1.00–
2.06] from Model I demonstrated an increased risk for the period of 1–4 years, the
results from Model II did not reveal any significant difference in cancer risk
between users and non-users. Similarly, comparison between metformin users, as
well as sulfonylurea users and those without ADM resulted in the RRs indicating
an increased risk during 1–4 years of exposure in the unadjusted model, and no
differences in the risk after full adjustment. While some increase in RR during the
first years after ADM initiation and a gradual decline during following years could
be suggested based on the results from the unadjusted models, no noticeable
variation in risk remained after adjustment for age, gender, calendar time, BMI,
and smoking (Figure 1). The results for tobacco-related cancers suggested similar
changes in RR in relation to exposure duration, although no significant
differences in risk were detected between users and non-users after adjustment
(Table S4).
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We found no elevated risk associated with the duration of insulin treatment
divided into periods of #1, 1–4, and .4 years when compared to those without
ADM (Table 3). The start of insulin treatment within 0–3 years after the initiation
of OADM was associated with a higher cancer risk, RR being 3.12 [95% CI 1.12–
6.72] when no adjustment was performed. However, no association was found
after adjustment [RR 2.28, 95% CI 0.82–4.94]. The results did not indicate any
association between the use of insulin and cancer when insulin treatment
commenced more than three years after the initiation of OADM.
Discussion
In this study on FINRISK cohorts, we analyzed the effect of ADM on cancer risk.
The findings of the study do not provide evidence of either beneficial or adverse
effects of anti-diabetic medication on cancer risk. One possible explanation for
this can be the small number of ADM users and cancer cases among them
compared to the non-users, which results in insufficient power to detect the
overall association between ADM and cancer risk. Likewise, due to the limited
data, the potential for heterogeneous association between different cancer types
and ADM could not be addressed comprehensively, as the stratification by cancer
sites was not possible. Overall, the association between ADM and cancer risk,
Table 2. Risk ratio of cancer incidence for users of ADM vs. non-users according to treatment.
1,000
PY
Cancer
cases, N
Crude IR/1,000
PY (95% CI)
Crude RR
(95% CI) p value
RR, Model I
(95% CI)
p
value
RR, Model II
(95% CI)
p
value
No ADM 192.21 1,028 5.35
(5.02–5.69)
1.00
(reference)
1.00 (reference) 1.00 (reference)
Any ADM 5.34 53 9.93
(7.44–13.00)
1.86
(1.39–2.42)
,0.001 1.08 (0.81–1.42) 0.574 1.01 (0.75–1.33) 0.926
Metformin exposure
ADM except metformin 0.81 11 13.66
(6.82–24.45)
2.55
(1.32–4.39)
0.002 1.32 (0.69–2.31) 0.367 1.28 (0.66–2.21) 0.418
Metformin 4.53 42 9.27
(6.67–12.53)
1.73
(1.25–2.32)
,0.001 1.03 (0.72–1.34) 0.829 0.96 (0.69–1.30) 0.799
Sulfonylurea exposure
ADM except sulfonylurea 3.19 31 9.70
(6.59–13.78)
1.81
(1.24–2.54)
0.001 1.17 (0.80–1.65) 0.382 1.09 (0.74–1.55) 0.898
Sulfonylurea 2.14 22 10.27
(6.43–15.55)
1.91
(1.22–2.85)
0.002 0.99 (0.63–1.47) 0.950 0.93 (0.57–1.39) 0.718
Insulin exposure
ADM except insulin 4.45 42 9.43
(6.79–12.75)
1.76
(1.28–2.37)
,0.001 1.02 (0.74–1.38) 0.876 0.95 (0.69–1.29) 0.771
Insulin 0.88 11 12.46
(6.22–22.30)
2.33
(1.21–4.00)
0.005 1.43(0.74–2.46) 0.242 1.36 (0.70–2.36) 0.308
Model I: Adjusted for age, gender, calendar time.
Model II: Adjusted for age, gender, calendar time, BMI, smoking status, interaction of age and gender, age and BMI.
Abbreviations: ADM, anti-diabetic medication; N, number of incident cancer cases; IR, incidence rate; PY, person-years; RR, risk ratio; CI, confidence
intervals.
doi:10.1371/journal.pone.0113162.t002
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Table 3. Variation in the cancer risk ratio in relation to exposure duration for users of ADM compared to non-users.
1,000
PY
Cancer
cases, N
Crude IR/1,000
PY (95% CI)
Crude RR
(95% CI) p value
RR, Model I
(95% CI)
p
value
RR, Model II
(95% CI)
p
value
No ADM 192.21 1,028 5.35
(5.02–5.69)
1.00
(reference)
1.00 (reference) 1.00 (reference)
ADM duration
ADM #1 year 1.19 7 5.86
(2.35–12.07)
1.10
(0.47–2.12)
0.810 0.68 (0.29–1.32) 0.312 0.65 (0.28–1.26) 0.250
ADM 1–4 years 2.37 31 13.07
(8.87–18.56)
2.44
(1.67–3.43)
,0.001 1.47 (1.00–2.06) 0.036 1.37 (0.94–1.94) 0.087
ADM .4 years 1.77 15 8.47
(4.74–13.98)
1.58
(0.91–2.54)
0.076 0.85 (0.49–1.37) 0.547 0.79 (0.45–1.28) 0.380
Metformin duration
ADM except metformin 0.81 11 13.66
(6.82–24.45)
2.55
(1.32–4.39)
0.002 1.34 (0.69–2.31) 0.367 1.28 (0.66–2.21) 0.418
Metformin ,1 year 1.09 5 4.59
(1.49–10.72)
0.86
(0.31–1.85)
0.734 0.53 (0.19–1.15) 0.169 0.51 (0.18–1.10) 0.131
Metfromin 1–4 years 2.10 28 13.34
(8.86–19.30)
2.50
(1.67–3.56).
0.002 1.46 (0.99–2.09) 0.030 1.41 (0.94–2.02) 0.079
Metformin .4 years 1.35 9 6.69
(3.06–12.71)
1.25
(0.60–2.26)
0.503 0.67 (0.32–1.21) 0.285 0.64 (0.31–1.17) 0.187
Sulfonylurea duration
ADM except sulfonylurea 3.19 31 9.70
(6.59–13.78)
1.81
(1.24–2.54)
0.001 1.26 (0.86–1.78) 0.202 1.19 (0.81–1.69) 0.345
Sulfonylurea ,1 year 0.35 3 8.47
(1.74–24.76)
1.58
(0.39–4.12)
0.426 0.80 (0.20–2.08) 0.702 0.77 (0.19–2.02) 0.659
Sulfonylurea 1–4 years 0.87 13 15.00
(7.98–25.66)
2.80
(1.87–5.22)
,0.001 1.46 (0.80–2.41) 0.179 1.40 (0.77–2.33) 0.226
Sulfonylurea .4 years 0.92 6 6.51
(2.38–14.17)
0.80
(0.25–1.88)
0.633 0.64 (0.25–1.30) 0.277 0.61 (0.24–1.24) 0.226
Insulin duration
ADM except insulin 12.67 42 9.43
(6.79–12.75)
1.76
(1.28–2.37)
,0.001 1.02(0.74–1.38) 0.877 0.95 (0.69–1.29) 0.771
Insulin #1 year 0.20 3 14.73
(3.03–43.04)
2.75
(0.68–7.15)
0.079 1.71 (0.42–4.44) 0.355 1.64 (0.41–4.27) 0.394
Insulin 1–4 years 0.40 5 12.58
(4.04–29.13)
2.35
(0.84–5.03)
0.056 1.44 (0.51–3.10) 0.420 1.35 (0.48–2.92) 0.501
Insulin .4 years 0.28 3 10.76
(2.22–31.46)
1.99
(0.50–5.23)
0.226 1.21 (0.30–3.16) 0.738 1.18 (0.29–3.08) 0.773
Duration of OADM
OADM only 4.45 42 9.43
(6.79–12.75)
1.76
(1.28–2.37)
,0.001 0.99 (0.72–1.33) 0.909 0.95 (0.68–1.28) 0.741
OADM #3y and insulin 0.30 5 16.68
(5.41–38.93)
3.12
(1.12–6.72)
0.011 2.26 (0.81–4.88) 0.054 2.28 (0.82–4.94) 0.066
OADM .3y and insulin 0.58 6 12.46
(6.22–22.30)
1.92
(0.76–3.91)
0.110 1.05 (0.42–2.14) 0.861 1.02 (0.41–2.09) 0.953
Model I: Adjusted for age, gender, calendar time.
Model II: Adjusted for age, gender, calendar time, BMI, smoking status, interaction of age and gender, age, and BMI.
Abbreviations: ADM, anti-diabetic medication; OADM, oral anti-diabetic medication; N, number of incident cancer cases; IR, incidence rate; PY, person-
years; RR, risk ratio; CI, confidence intervals.
doi:10.1371/journal.pone.0113162.t003
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which may exist for some cancers but not others, could not be ruled out based on
the results of this study.
Primary focus of this study was to determine exposure to ADM in terms of
treatment duration and to assess its effect on cancer risk. Several studies have
demonstrated that time-varying representation of exposure is a meaningful
component when exploring the link between diabetes or ADM and cancer risk
[7,8,19]. Indeed, comparison of the results from analyses accounting for the
duration of ADM with those from analyses ignoring the duration effect attests to
the importance of considering timing.
Figure 1. Cancer incidence rate ratio for ADM users vs. non-users. Results from spline models A - with no
adjustment, B - adjusted for age, gender, calendar time, BMI, and smoking status (including interactions of
age and gender; age and BMI). For metformin and sulfonylurea, allocation of RR .1 at the initiation refers to
the effect of being already treated with other anti-diabetic medicines. Thick dashed lines indicate 95% CIs, thin
horizontal dotted line is a reference line for no effect, tick marks along the base of plot for cancers occurred
among users.
doi:10.1371/journal.pone.0113162.g001
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In addition, we addressed the role of factors influencing the risk of both
diabetes and cancer. We found a considerable discrepancy between diabetic and
non-diabetic populations in the distribution of risk factors such as age, gender,
BMI, and smoking. Moreover, we observed that these factors modify both the
cancer risk and the probability of starting ADM, with patterns of risk being
relatively similar. Only a limited number of observational studies have accounted
for the effect of common risk factors, and there is still a need for a thorough
evaluation of the impact of confounding factors [20,21].
The changes in RRs observed as a result of the adjustment are in accordance
with knowledge of the strong modifying effect of age, gender, BMI, and smoking
on cancer risk. Increasing age is related to an increased risk of many diseases,
including diabetes and cancer [22,23]. Aging is also related to an increase in BMI,
and thus can also affect the choice of medication [24]. Obesity is the most
common co-morbidity of diabetes, and it is strongly associated with an increased
risk of type 2 diabetes, as well as with higher risk of certain cancers [25]. Smoking
is another lifestyle factor that is known to be related to both cancer and diabetes
[26,27]. Thus, only taking into account age, gender, and calendar time, which is
the case in nationwide studies, may lead to biased results.
To draw conclusions on causality, both short-term and long-term exposure
effects should be explored. In this study, the exposure of interest was specified in a
manner allowing assessment of the variation in risk in relation to exposure
duration. Although no significant association between the duration of ADM and
cancer risk was found, the results revealed a disadvantage of analyses performed
without considering the treatment duration due to the averaging of risk values
over the entire period.
Some previous cohort studies have considered detection bias, reverse causality
and/or indication bias as the plausible explanations for the peak in cancer risk
found at the time of diabetes onset or in the early period after treatment initiation
[7,8,19]. The development of cancer can be accompanied by an abnormal
metabolic process, which is likely to be diagnosed first [9,12,28]. On the other
hand, detection bias can be introduced due to the extensive screening usually
following the initiation of ADM, which can then be associated with an increased
probability of the early detection of occult cancer. This type of bias can probably
be addressed by performing analysis that accounts for cancer severity at the onset
or the number of physician visits [29].
We found that those who have used ADM, particularly metformin, for 1–4
years as well as those who started insulin use within 0–3 years after the
initiation of oral anti-diabetic medication might be at higher risk of cancer.
Reverse causality and bias in cancer detection might also be encountered at the
time of initiation when starting a new treatment, especially if the initial one has
not been beneficial or effective, and an additional or alternative treatment is
necessary. The choice of a particular medicine as the first option and the
sequence of adding new medicines to the treatment indicate the severity of
diabetes and presence of comorbidities [30]. Metformin is the first-line
treatment for most patients with type 2 diabetes, while insulin secretagogues
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and insulin are usually added on later if needed [31]. Thus, rapid progression
from the initiation of OADM to the requirement for insulin treatment can be a
sign of a worsening health status and can be seen as a potential risk factor for
cancer. On the other hand, indication bias might be present due to the
allocation of treatment, as assignment is based on strong recommendations
[32].
In this study, high-quality register data from the Finnish Cancer Registry and
Prescription Register allowed the effective exclusion of individuals with a cancer
history at baseline and prevalent users of ADM. By using new-user design we
avoided prevalent user bias, while by defining the start of follow-up similarly for
both users and non-users, and by applying appropriate method of analysis we
eluded immortal time bias, which arises from the misclassification of the person-
time. In addition, it was possible to evaluate the variation of in cancer risk due to
the technique of data analysis used. Moreover, the information on common risk
factors recorded in the FINRISK survey made it possible to address potential
confounding, which is one of the key biases in identifying causal effects. The
participation rates in the FINRISK surveys were relatively high in the period
considered by this study, making non-response bias unlikely.
One of the disadvantages of the study was the inability to distinguish
between diabetes types, although only eight individuals started with insulin
treatment under the age of 35 years, suggesting a minor contribution of
patients with type 1 diabetes. Seemingly, also a lack of the date of diabetes
onset is a subject likely to affect the results. Diabetic patients are at highest risk
of cancer at the time of diagnosis of diabetes, though an increased cancer risk
may even be present in the prediabetic period [7,8,33]. Indeed, the actual
duration of exposure to elevated insulin levels cannot be reliably assessed even
when precise date of diagnosis was known, as insulin resistance can predate
the diagnosis of diabetes by up to 10 years [34]. In Finland, about 25% of
patients diagnosed with diabetes are not included in the Prescription Register,
either because of not receiving medication at all or because of inpatient care
[35]. Thus, in this study some diabetic patients are likely to be included into
reference population. This kind of disadvantage seems to be common to
observational studies, as up to 50% of those with diabetes remain undiagnosed
in European countries [36–38]. Other noteworthy limitations in this study
were the lack of information on dosage and the analysis performed for all
cancer sites combined.
Well-designed observational studies carried out using high-quality data
sources and based on large samples with a long follow-up time and extensive
covariate information, including the date of the onset of diabetes, treatment
details, and common risk factors, would provide the greatest efficiency in
exploring the relationship between ADM and cancer risk, especially if only a
minor effect of ADM on the cancer risk could be suggested. Obviously, one of
the key issues is the examination of cancer risk, which, if carried out according to
specific sites, enables the capturing of the biological link between ADM and
cancer risk. Furthermore, the detection of an association not only relies on the
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quality of data and the study design, but also on the approach used to represent
the drug exposure. Along with the effect of ADM/diabetes duration, other
relevant aspects such the dose–response relationship and drug persistence should
be considered, if detailed information on medication is available. Given such
complexity, it is important to use the appropriate analysis techniques and to
accurately interpret the findings.
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